Cargando…
Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children
BACKGROUND: This trial was conducted to evaluate the safety and immunogenicity of two virosome formulated malaria peptidomimetics derived from Plasmodium falciparum AMA-1 and CSP in malaria semi-immune adults and children. METHODS: The design was a prospective randomized, double-blind, controlled, a...
Autores principales: | Cech, Patrick Georges, Aebi, Thomas, Abdallah, Mwanajaa Shomari, Mpina, Maxmillian, Machunda, Ester Barnabas, Westerfeld, Nicole, Stoffel, Sabine Alexandra, Zurbriggen, Rinaldo, Pluschke, Gerd, Tanner, Marcel, Daubenberger, Claudia, Genton, Blaise, Abdulla, Salim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142124/ https://www.ncbi.nlm.nih.gov/pubmed/21799810 http://dx.doi.org/10.1371/journal.pone.0022273 |
Ejemplares similares
-
A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers
por: Genton, Blaise, et al.
Publicado: (2007) -
Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations
por: Tamborrini, Marco, et al.
Publicado: (2011) -
Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine
por: Tamborrini, Marco, et al.
Publicado: (2009) -
A Virosomal Malaria Peptide Vaccine Elicits a Long-Lasting Sporozoite-Inhibitory Antibody Response in a Phase 1a Clinical Trial
por: Okitsu, Shinji L., et al.
Publicado: (2007) -
Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial
por: Thompson, Fiona M., et al.
Publicado: (2008)